These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 29463999)

  • 1. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
    Zhou L; Wang H; Li Y
    Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Approaches of Dual-targeted Nanomedicines for Tumor Multidrug Resistance.
    Han W; Shen Z; Zou J; Ye Q; Ge C; Zhao Y; Wang T; Chen Y
    Curr Drug Deliv; 2024; 21(2):155-167. PubMed ID: 37143266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
    Gote V; Nookala AR; Bolla PK; Pal D
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
    Zhang Y; Li J; Pu K
    Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
    He Q; Shi J
    Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming multidrug resistance with nanomedicines.
    Ganoth A; Merimi KC; Peer D
    Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer.
    Maimaitijiang A; He D; Li D; Li W; Su Z; Fan Z; Li J
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor.
    Yin Q; Shen J; Zhang Z; Yu H; Li Y
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1699-715. PubMed ID: 23611952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer nanomedicines harnessing tumor microenvironmental components.
    Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
    Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
    Petrikaite V; D'Avanzo N; Celia C; Fresta M
    Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
    Mao C; Li F; Zhao Y; Debinski W; Ming X
    Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
    Tekchandani P; Kurmi BD; Paliwal SR
    Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
    Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
    Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicine solutions to intricate physiological-pathological barriers and molecular mechanisms of tumor multidrug resistance.
    Li Y; Xu X
    J Control Release; 2020 Jul; 323():483-501. PubMed ID: 32387548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
    Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
    Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.